Cyteir Therapeutics
Get verified emails for Cyteir Therapeutics employees
About Cyteir Therapeutics
|
|
|
11-50 employees
View all
|
|
Research
|
|
128 Spring St, Building A, Suite 510, Lexington, MA 02421, US
|
|
Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
|
Cyteir Therapeutics Email Format
The widely used Cyteir Therapeutics email format is {first}.{last}@cyteir.com (e.g. [email protected]), which is used 50% of the time.
| Cyteir Therapeutics Email Formats | Example Email Formats | Percentage |
|---|---|---|
| {first}.{last} | [email protected] |
50%
|
Cyteir Therapeutics Alternatives
Frequently Asked Questions about Cyteir Therapeutics
What is Cyteir Therapeutics email format?
The widely used Cyteir Therapeutics email format is {first}.{last} (e.g. [email protected]) with 50% adoption across the company.
What is Cyteir Therapeutics customer service number?
To contact Cyteir Therapeutics customer service number in your country click here to find.
Who is the CEO of Cyteir Therapeutics?
Markus Renschler is the CEO of Cyteir Therapeutics.
Cyteir Therapeutics Staff Directory
Search Cyteir Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Search Portal
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
